Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy in brain metastases.

David M Peereboom1

  • 1Cleveland Clinic Brain Tumor Institute, Hematology/Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA. peerebd@ccf.org

Neurosurgery
|October 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Nature medicine·2026
Same author

Racial Disparities in Glioblastoma: Can We Untangle Biological From Nonbiological Forces?

JCO oncology practice·2026
Same author

Role of Immunotherapy and Targeted Agents to Treat Brain Metastases.

Cancer journal (Sudbury, Mass.)·2026
Same author

Intracerebral hemorrhage risk in glioma patients taking direct oral anticoagulants as compared with low molecular weight heparin.

Neuro-oncology advances·2025
Same author

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma.

Neuro-oncology·2025

Systemic chemotherapy for brain metastases shows promise with new agents like temozolomide. Future trials should explore novel agents and delivery methods for improved patient outcomes in brain cancer treatment.

Area of Science:

  • Neuro-oncology
  • Medical Oncology

Background:

  • Chemotherapy for brain metastases has historically faced skepticism due to unproven survival benefits.
  • Novel agents and delivery techniques necessitate a re-evaluation of chemotherapy's role.

Purpose of the Study:

  • To review clinical data from the past decade on chemotherapy for brain metastases.
  • To emphasize trial design, histology, agents, and multimodality strategies.
  • To discuss techniques for circumventing the blood-brain barrier.

Main Methods:

  • Review of clinical data from the last 10 years.
  • Analysis of trial design, tumor histology, and available chemotherapeutic agents.
  • Examination of multimodality strategies and regional delivery techniques.

Related Experiment Videos

Main Results:

  • Temozolomide shows encouraging results in non-small cell lung cancer brain metastases.
  • Implanted carmustine wafers achieve excellent local tumor control rates.
  • Chemotherapy, often a salvage therapy, may benefit selected newly diagnosed patients.

Conclusions:

  • Chemotherapy may be considered for selected patients with newly diagnosed brain metastases.
  • Future trials should investigate novel agents pre-irradiation and enhanced regional delivery.
  • Phase III trials stratified by histology and prognostic factors are needed to define chemotherapy's role.